Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction

Science Translational Medicine

Volumn 6, Issue 223, 2014, Pages

  Eckhouse, Shaina R ^a   Purcell, Brendan P ^b   McGarvey, Jeremy R ^c   Lobb, David ^d   Logdon, Christina B ^d   Doviak, Heather ^d   O'Neill, Jason W ^e   Shuman, James A ^d   Novack, Craig P ^d   Zellars, Kia N ^d   Pettaway, Sara ^d   Black, Roy A ^e   Khakoo, Aarif ^e   Lee, TaeWeon ^e   Mukherjee, Rupak ^a   Gorman, Joseph H ^c   Gorman, Robert C ^c   Burdick, Jason A ^b   Spinale, Francis G ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYALURONIC ACID; RECOMBINANT TISSUE INHIBITOR OF METALLOPROTEINASE 3; SMOOTH MUSCLE ACTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; HYDROGEL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RELEASE; ECHOCARDIOGRAPHY; FLUOROSCOPY; HEART DILATATION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HYDROGEL; INFLAMMATION; LEFT VENTRICULAR REMODELING; MYOFIBROBLAST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MYOCARDIAL INFARCTION; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HYDROGEL; MYOCARDIAL INFARCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3; VENTRICULAR REMODELING;

EID: 84896350465     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007244     Document Type: Article

References (26)

1. F. G. Spinale, Myocardial matrix remodeling and the matrix metalloproteinases. Influence on cardiac form and function. Physiol. Rev. 87, 1285-1342 (2007).
2. R. Mukherjee, T. A. Brinsa, K. B. Dowdy, A. A. Scott, J. M. Baskin, A. M. Deschamps, A. S. Lowry, G. P. Escobar, D. G. Lucas, W. M. Yarbrough, M. R. Zile, F. G. Spinale, Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107, 618-625 (2003).
3. F. G. Spinale, C. N. Koval, A. M. Deschamps, R. E. Stroud, Dynamic changes in matrix metalloproteinase activity within the human myocardial interstitium during ischemia reperfusion. Circulation 118 (Suppl. 14), S16-S23 (2008).
4. C. S. Webb, D. D. Bonnema, S. H. Ahmed, A. H. Leonardi, C. D. McClure, L. L. Clark, R. E. Stroud, W. C. Corn, L. Finklea, M. R. Zile, F. G. Spinale, Specific temporal profile of matrix metalloproteinase release occurs in patients following myocardial infarction: Relation to left ventricular remodeling. Circulation 114, 1020-1027 (2006).
5. G. Dormán, S. Cseh, I. Hajdú, L. Barna, D. Kónya, K. Kupai, L. Kovács, P. Ferdinandy, Matrix metalloproteinase inhibitors: A critical appraisal of design principles and proposed therapeutic utility. Drugs 70, 949-964 (2010).
6. K. Brew, D. Dinakarpandian, H. Nagase, Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283 (2000).
7. E. M. Wilson, S. L. Moainie, J. M. Baskin, A. S. Lowry, A. M. Deschamps, R. Mukherjee, T. S. Guy, M. G. St John-Sutton, J. H. Gorman III, L. H. Edmunds Jr., R. C. Gorman, F. G. Spinale, Region and species specific induction of matrix metalloproteinases occurs with post-myocardial infarction remodeling. Circulation 107, 2857-2863 (2003).
8. J. D. Lovelock, A. H. Baker, F. Gao, J. F. Dong, A. L. Bergeron, W. McPheat, N. Sivasubramanian, D. L. Mann, Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 288, H461-H468 (2005).
9. Z. Kassiri, V. Defamie, M. Hariri, G. Y. Oudit, S. Anthwal, F. Dawood, P. Liu, R. Khokha, Simultaneous transforming growth factor b-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J. Biol. Chem. 284, 29893-29904 (2009).
10. W. H. Yu, S. Yu, Q. Meng, K. Brew, J. F. Woessner Jr., TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J. Biol. Chem. 275, 31226-31232 (2000).
11. J. L. Ifkovits, E. Tous, M. Minakawa, M. Morita, J. D. Robb, K. J. Koomalsingh, J. H. Gorman III, R. C. Gorman, J. A. Burdick, Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc. Natl. Acad. Sci. U.S.A. 107, 11507-11512 (2010).
12. R. Mukherjee, J. A. Zavadzkas, S. M. Saunders, J. E.McLean, L. B. Jeffords, R. E. Stroud, A. M. Leone, C. N. Koval, W. T. Rivers, S. Basu, A. Sheehy, G. Michal, F. G. Spinale, Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann. Thorac. Surg. 86, 1268-1276 (2008).
13. R. J. Lee, A. Hinson, S. Helgerson, R. Bauernschmitt, H. N. Sabbah, Polymer-based restoration of left ventricular mechanics. Cell Transplant. 22, 529-533 (2013).
14. J. A. Dixon, F. G. Spinale, Large animal models of heart failure: A critical link in the translation of basic science to clinical practice. Circ. Heart Fail. 2, 262-271 (2009).
15. A. S. Blom, J. J. Pilla, J. Arkles, L. Dougherty, L. P. Ryan, J. H. Gorman III, M. A. Acker, R. C. Gorman, Ventricular restraint prevents infarct expansion and improves borderzone function after myocardial infarction: A study using magnetic resonance imaging, three-dimensional surface modeling, and myocardial tagging. Ann. Thorac. Surg. 84, 2004-2010 (2007).
16. M. R. Zile, S. M. Desantis, C. F. Baicu, R. E. Stroud, S. B. Thompson, C. D. McClure, S. M. Mehurg, F. G. Spinale, Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ. Heart Fail. 4, 246-256 (2011).
17. W. S. Colucci, E. Braunwald, Pathophysiology of Heart Failure. Braunwald 's Heart Disease: A Textbook of Cardiovascular Medicine (Elsevier, Philadelphia, PA, 2005).
18. F. G. Spinale, J. S. Janicki, M. R. Zile, Membrane-associated matrix proteolysis and heart failure. Circ. Res. 112, 195 -208 (2013).
19. A. Ducharme, S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, L. E. Rohde, F. J. Schoen, R. A. Kelly, Z. Werb, P. Libby, R. T. Lee, Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106, 55-62 (2000).
20. A. Amour, P. M. Slocombe, A. Webster, M. Butler, C. G. Knight, B. J. Smith, P. E. Stephens, C. Shelley, M. Hutton, V. Knäuper, A. J. Docherty, G. Murphy, TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435, 39 -44 (1998).
21. K. J. Leco, R. Khokha, N. Pavloff, S. P. Hawkes, D. R. Edwards, Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. 269, 9352-9360 (1994).
22. N. G. Frangogiannis, Regulation of the inflammatory response in cardiac repair. Circ. Res. 110, 159-173 (2012).
23. J. Baum, H. S. Duffy, Fibroblasts and myofibroblasts: What are we talking about? J. Cardiovasc. Pharmacol. 57, 376-379 (2011).
24. LoneStar Heart Inc., A randomized, controlled study to evaluate Algisyl-LVR™ as a method of left ventricular augmentation for heart failure (AUGMENT-HF), 2011-2012, NLM identifier: NCT01311791; http://clinicaltrials.gov/ct2/show/NCT01311791.
25. D. C. Lee, M. C. Oz, A. D. Weinberg, W. Ting, Appropriate timing of surgical intervention after transmural acute myocardial infarction. J. Thorac. Cardiovasc. Surg. 125, 115-119 (2003).
26. NIH, Guide for the Care and Use of Laboratory Animals (NIH, Washington, DC, ed. 8, 2011).